Tarsus Pharmaceuticals, Inc. — Director's Dealing 2023

Apr 21, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Tarsus Pharmaceuticals, Inc. (TARS)
CIK: 0001819790
Period of Report: 2023-04-19

Reporting Person: Azamian Bobak R. (Director, President/CEO and Board Chair)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-04-19	Common Stock	S	8000	$13.60	Disposed	1072536	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	8597	Direct

Footnotes

F1: The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 14, 2022.

F2: The price reported in column 4 is a weighted average price. The shares were pooled and sold in multiple transactions at prices ranging from $13.13 to $14.03. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The Reporting Person is the trustee of the Bobak Azamian Living Trust, established April 16, 2018 and has voting and dispositive power with respect to these shares.